Anavex Life Sciences Corp AVXL

Healthcare Biotechnology

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). The Company’s product candidates include NAVEX 3-71, ANAVEX 1-41, and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1-41 is a sigma-1 agonist.

NDAQ:AVXL - Post by User

Anavex Life Sciences Corp

Bullboard Posts

Next >>

Post by R_J_on Dec 01, 2019 7:58am

129 Views

Post# 30410222

End of Month - November 2019

End of the Month (EOM) report for November 2019.
-
AVXL closed on 11/29/2019 at US$2.40
AVXL closed on 10/31/2019 at US$2.72
-
This is a 11.8%, a 32-cent, loss for November.
-
S&P 500 Index, @ 3140.9 gained 3.4% in November. [7.3% above its MA(200) @ 2,927.1]
-
Two Hundred Day Moving Average [MA(200)] stuff.
AVXL's MA(200) ended November at $2.90
AVXL is now 17.2% below its MA(200).
-
News Releases on the AVXL Website in November
-
Use this link to see and read the all of November’s News Releases.
-
https://www.anavex.com/2019/11/
-
RJ

Bullboard Posts

Next >>

Here are three global stocks you should watch